Diabetes Research and Clinical Practice
Volume 75, Issue 3 , Pages 339-347 , March 2007

Pharmacy diabetes care program: Analysis of two screening methods for undiagnosed type 2 diabetes in Australian community pharmacy

  • I. Krass

      Affiliations

    • Faculty of Pharmacy, Sydney University, NSW 2006, Australia
    • Corresponding Author InformationCorresponding author. Tel.: +61 2 9351 3507; fax: +61 2 9351 4451.
    • ,
  • B. Mitchell

      Affiliations

    • Faculty of Pharmacy, Sydney University, NSW 2006, Australia
    • ,
  • P. Clarke

      Affiliations

    • School of Public Health, University of Sydney, Australia
    • ,
  • M. Brillant

      Affiliations

    • Faculty of Pharmacy, Sydney University, NSW 2006, Australia
    • ,
  • R. Dienaar

      Affiliations

    • Tasmanian School of Pharmacy, University of Tasmania, Australia
    • ,
  • J. Hughes

      Affiliations

    • School of Pharmacy, Curtin University, Australia
    • ,
  • P. Lau

      Affiliations

    • Victorian College of Pharmacy, Monash University, Australia
    • ,
  • G. Peterson

      Affiliations

    • Tasmanian School of Pharmacy, University of Tasmania, Australia
    • ,
  • K. Stewart

      Affiliations

    • Victorian College of Pharmacy, Monash University, Australia
    • ,
  • S. Taylor

      Affiliations

    • Faculty of Pharmacy, Sydney University, NSW 2006, Australia
    • ,
  • J. Wilkinson

      Affiliations

    • School of Pharmacy, Curtin University, Australia
    • ,
  • C. Armour

      Affiliations

    • Faculty of Pharmacy, Sydney University, NSW 2006, Australia

Received 24 April 2006 ,Accepted 22 June 2006.

References 

  1. Dunstan DW, Zimmet PZ, Welborn TA, De Courten MP, Cameron AJ, Sicree RA, et al. The rising prevalence of diabetes and impaired glucose tolerance: The Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care. 2002;25(5):829–834
  2. S. Colagiuri, P. Zimmet, A. Hepburn, R. Colagiuri, Evidence Based Guidelines for type 2 diabetes: Primary Prevention, Case Detection and Diagnosis, Canberra, Australia, Diabetes Australia and National Health and Medical Research Council. Available at http://www.nhmrc.gov.au/publications/_files/cp86.pdf. Update available at http://www.diabetesaustralia.com.au/_lib/doc_pdf/NEBG/P1/Part1-Introduction-Jul05.pdf. Last accessed 9th March 2006.
  3. UK Prospective Diabetes Study (UKPDS) Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853(see comment)(erratum appears in Lancet 1999 Aug 14;354(9178):602)
  4. UK Prospective Diabetes Study (UKPDS) Group . Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care. 1999;22(7):1125–1136
  5. Pharmaceutical Society of Australia, Australian Pharmacy—Primary Health Care's forgotten resource, A submission to the Review of the Role of Primary Health care in Health Promotion in Australia, Pharmaceutical Society of Australia, Canberra, July 1991.
  6. Teh R, Chen T, Krass I. Consumer perspectives of pharmacist-delivered health promotion and screening services. Int. J. Pharm. Pract. 2001;9:261–267
  7. McElnay J, Nicholl A, Grainger-Rousseau T. The role of community pharmacist—a survey of public opinion in N. Ireland. Int. J. Pharm. Pract. 1993;2:95–100
  8. http://www.qcpp.com/pharmacy_standards_checklist_july04.pdf. Last accessed 9th March 2006.
  9. Dietary Guidelines for Australian Adults, Department of Health and Ageing, Canberra, 1999.
  10. National Physical Activity Guidelines for Australians, Department of Health and Ageing, Canberra, 1999.
  11. Briggs A, Clark T, Wolstenholme J, Clarke P. Missing … presumed at random: cost-analysis of incomplete data. Health Econ. 2003;12(5):377–392
  12. I. Krass, C. Armour, S. Taylor, G.M. Peterson, K. Stewart, J.M. Hughes, Pharmacy Diabetes Care Program. Final Report: University of Sydney, 2005. http://beta.guild.org.au/uploadedfiles/Research_and_Development_Grants_Program/Projects/2002-518_fr.pdf. Last accessed 31st March 2006.
  13. Colagiuri SMD, Hussain ZMSC, Zimmet PMD, Cameron AMPH, Shaw JMD. Screening for type 2 diabetes and impaired glucose metabolism: the Australian experience. Diabetes Care. 2004;27(2):367–371
  14. Engelgau M, Narayan K, Herman W. Screening for type 2 diabetes. Diabetes Care. 2000;23(10):1563–1580
  15. Ealovega MW, Tabaei BP, Brandle M, Burke R, Herman WH. Opportunistic screening for diabetes in routine clinical practice. Diabetes Care. 2004;27(1):9–12
  16. Leiter LA, Barr A, Belanger A, Lubin S, Ross SA, Tildesley HD, et al. Diabetes Screening in Canada (DIASCAN) Study: prevalence of undiagnosed diabetes and glucose intolerance in family physician offices. Diabetes Care. 2001;24(6):1038–1043
  17. Christensen JO, Sandbaek A, Lauritzen T, Borch-Johnsen K. Population-based stepwise screening for unrecognised type 2 diabetes is ineffective in general practice despite reliable algorithms. Diabetologia. 2004;47(9):1566–1573
  18. Zhang P, Engelgau MM, Valdez R, Benjamin SM, Cadwell B, Venkat Narayan KM. Costs of screening for pre-diabetes among U.S. adults: a comparison of different screening strategies. Diabetes Care. 2003;26(9):2536–2542
  19. Adriaanse MC, Snoek FJ, Dekker JM, Spijkerman AMW, Nijpels G, van der Ploeg HM, et al. Perceived risk for Type 2 diabetes in participants in a stepwise population-screening programme. Diabet. Med. 2003;20(3):210–215

PII: S0168-8227(06)00291-9

doi: 10.1016/j.diabres.2006.06.022

Diabetes Research and Clinical Practice
Volume 75, Issue 3 , Pages 339-347 , March 2007

Article Tools

* Image Usage & Resolution